Ratings Federated Hermes, Inc.

Equities

FHI

US3142111034

Real-time Estimate Cboe BZX Other stock markets 12:27:55 2024-05-31 pm EDT			5-day change	1st Jan Change
32.72 ^USD	+0.17%		+0.46%	-3.46%

May. 07	Zenas BioPharma, Inc. announced that it has received $200.145732 million in funding from a group of investors	CI
May. 03	Zenas BioPharma, Inc. announced that it expects to receive $200.145732 million in funding	CI

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The company returns high margins, thereby supporting business profitability.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
This company will be of major interest to investors in search of a high dividend stock.
Over the last twelve months, the sales forecast has been frequently revised upwards.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Investment Management & Fund Operators

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
FEDERATED HERMES, INC.	-3.46%	2.62B		C
KKR & CO. INC.	+22.84%	92.14B		C+
BLACKSTONE INC.	-9.82%	90.59B		C-
ARES MANAGEMENT CORPORATION	+18.50%	27.84B		B-
LEGAL & GENERAL PLC	-0.44%	18.94B	-	B+
AMUNDI	+14.69%	15.57B		B
THE CARLYLE GROUP INC.	+4.15%	15.33B		C+
FRANKLIN RESOURCES, INC.	-21.77%	12.13B		C+
BLUE OWL CAPITAL INC.	+23.42%	10.07B		C-
HDFC ASSET MANAGEMENT COMPANY LIMITED	+21.20%	9.61B		B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes